Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 12,475 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cell Therapy Clear all
Completed Phase 2 Interventional Results available

Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT02086552
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Laboratory Biomarker Analysis, Lenalidomide, Sonidegib
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 30, 2026, 1:12 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

NCT01126749
View directory record Official record
Conditions
Bladder Cancer
Interventions
Gemcitabine, E7389, Cisplatin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • Fort Myers, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 30, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer

NCT02370238
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
paclitaxel, Reparixin, placebo
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older · Female only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
32
States / cities
Mobile, Alabama • Bakersfield, California • Daytona Beach, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 30, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme

NCT00323115
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Autologous Dendritic Cell, Temozolomide, Radiotherapy, Dendritic Cell Vaccine
Biological · Drug · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 30, 2026, 1:12 PM EDT
Completed Not applicable Interventional

Rejuvenation of Premature Ovarian Failure With Stem Cells

NCT02696889
View directory record Official record
Conditions
Primary Ovarian Insufficiency, Low Ovarian Reserve, Premature Ovarian Failure
Interventions
ROSE-1 Protocol
Procedure
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 30, 2026, 1:12 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

NCT06104618
View directory record Official record
Conditions
Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Unresectable Penile Squamous Cell Carcinoma
Interventions
Enfortumab Vedotin, Computed Tomography, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 30, 2026, 1:12 PM EDT
Completed Not applicable Interventional

Palliative Care Intervention in Improving Symptom Control and Quality of Life in Patients With Stage II-IV Non-small Cell Lung Cancer and Their Family Caregivers

NCT02243748
View directory record Official record
Conditions
Caregiver, Psychological Impact of Cancer and Its Treatment, Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
Palliative Therapy, quality-of-life assessment, questionnaire administration
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Duarte, California • Irvine, California • Ontario, California + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 1:12 PM EDT
Completed Phase 1 Interventional Results available

Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

NCT00401778
View directory record Official record
Conditions
Lung Cancer
Interventions
RAD001
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Oct 30, 2026, 1:12 PM EDT
Completed Early Phase 1 Interventional

Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals

NCT01836068
View directory record Official record
Conditions
HIV
Interventions
Enfuvirtide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 30, 2026, 1:12 PM EDT
Completed Phase 1 Interventional

Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery

NCT03678350
View directory record Official record
Conditions
Malignant Mesothelioma, Non-Small Cell Lung Carcinoma, Pleural Disorder
Interventions
Light Dosimetry for Intranoperative Therapy, Photodynamic Therapy, Porfimer Sodium
Device · Procedure · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 30, 2026, 1:12 PM EDT
Completed Phase 1 Interventional

Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

NCT00033410
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, tirapazamine, radiation therapy
Drug · Radiation
Lead sponsor
California Cancer Consortium
Network
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Duarte, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Oct 30, 2026, 1:12 PM EDT
Withdrawn Phase 2 Interventional

SABR for T1-2a N1 NSCLC

NCT03321760
View directory record Official record
Conditions
Lung Cancer
Interventions
Stereotactic Ablative Radiation Therapy (SABR)
Radiation
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Oct 30, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

Mechlorethamine Induced Contact Dermatitis Avoidance Study

NCT03380026
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma, Cutaneous T-cell Lymphoma Stage I, Mycosis Fungoides, Folliculotropic Mycosis Fungoides, Granulomatous Slack Skin, Syringotropic Mycosis Fungoides, Mycosis Fungoides Variant, Transformed Mycosis Fungoides
Interventions
Triamcinolone, Valchlor 0.016 % Topical Gel
Drug
Lead sponsor
Rochester Skin Lymphoma Medical Group, PLLC
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Fairport, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 30, 2026, 1:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy

NCT04063215
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 30, 2026, 1:12 PM EDT
Completed Not applicable Interventional

Hematopoetic Stem Cell Transplant and Physical Function

NCT03103308
View directory record Official record
Conditions
Cancer, Walking
Interventions
Walk Training and Transplant, Activity Monitoring and Transplant
Other
Lead sponsor
University of Miami
Other
Eligibility
40 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 30, 2026, 1:12 PM EDT
Terminated Not applicable Interventional Results available

Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes

NCT02134717
View directory record Official record
Conditions
Sarcoidosis
Interventions
all subjects will receive maraviroc 300mg orally twice a day for 6 weeks, Bronchoscopy with bronchoalveolar lavage, venipunctures, Skin biopsy
Drug · Procedure
Lead sponsor
Kevin F. Gibson
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 30, 2026, 1:12 PM EDT
Recruiting Phase 1Phase 2 Interventional

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

NCT07335497
View directory record Official record
Conditions
Locally Advanced / Metastatic Solid Tumors
Interventions
CR-001, Paclitaxel, trifluridine and tipiracil, Pemetrexed, Carboplatin, Oxaliplatin, Gemcitabin, Cisplatin, Capecitabine, FOLFOX
Drug
Lead sponsor
Crescent Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

NCT02242097
View directory record Official record
Conditions
Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
Interventions
ibrutinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
5
States / cities
Chicago, Illinois • Lake Forest, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 30, 2026, 1:12 PM EDT
Completed Phase 1 Interventional

A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors

NCT00619424
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
pazopanib, erlotinib, pemetrexed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Aurora, Colorado • Buffalo, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 30, 2026, 1:12 PM EDT
Not listed Phase 2 Interventional

Chemotherapy, Surgery, Radiation Therapy and Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Primary CNS Germ Cell Tumors

NCT00025324
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, carboplatin, cyclophosphamide, etoposide, thiotepa, autologous bone marrow transplantation, bone marrow ablation with stem cell support, conventional surgery, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Los Angeles, California • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 30, 2026, 1:12 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Autologous Adipose-Derived Stromal Cells Delivered Into the Corpus Cavernous in Patients With Erectile Dysfunction

NCT02087397
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Liposuction, AD-SVF Cell Injection
Other · Biological
Lead sponsor
Ageless Regenerative Institute
Industry
Eligibility
18 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 30, 2026, 1:12 PM EDT
Completed Phase 1 Interventional

ACTolog in Patients With Solid Cancers

NCT02876510
View directory record Official record
Conditions
Cancer, Solid Tumor
Interventions
Fludarabine, Cyclophosphamide, IMA101 product, Recombinant human interleukin-2, IMADetect, Atezolizumab
Drug · Biological · Diagnostic Test
Lead sponsor
Immatics US, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 30, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)

NCT00488982
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Docetaxel and GM-CSF
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 30, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma

NCT01334515
View directory record Official record
Conditions
Recurrent Neuroblastoma
Interventions
hu14.18-IL2 fusion protein, isotretinoin, sargramostim, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
71
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Arcadia, California + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 30, 2026, 1:12 PM EDT